CN116712422A - 治疗特定患者群体的神经变性病症的方法 - Google Patents

治疗特定患者群体的神经变性病症的方法 Download PDF

Info

Publication number
CN116712422A
CN116712422A CN202310582365.9A CN202310582365A CN116712422A CN 116712422 A CN116712422 A CN 116712422A CN 202310582365 A CN202310582365 A CN 202310582365A CN 116712422 A CN116712422 A CN 116712422A
Authority
CN
China
Prior art keywords
subject
apoe4
disease
mild
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310582365.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿布沙克拉
A·鲍尔
M·托拉尔
J·海伊
J·于
P·科西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116712422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of CN116712422A publication Critical patent/CN116712422A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310582365.9A 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法 Pending CN116712422A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population
CN201680052760.4A CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680052760.4A Division CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Publications (1)

Publication Number Publication Date
CN116712422A true CN116712422A (zh) 2023-09-08

Family

ID=58240195

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680052760.4A Pending CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
CN202310582365.9A Pending CN116712422A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法
CN202310582394.5A Pending CN116712423A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680052760.4A Pending CN108289870A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310582394.5A Pending CN116712423A (zh) 2015-09-10 2016-09-09 治疗特定患者群体的神经变性病症的方法

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN108289870A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119911T (pt) 2014-03-21 2023-11-03 Alzheon Inc Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
HRP20230809T1 (hr) * 2015-09-10 2023-10-27 Alzheon, Inc. Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) * 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PT3829568T (pt) 2018-08-01 2023-12-14 Alzheon Inc Derivados de ácido sulfopropanoico para tratamento de distúrbios neurodegenerativos
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
UA129160C2 (uk) * 2019-06-17 2025-01-29 Алзхеон, Інк. Спосіб лікування хвороби альцгеймера
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023107658A1 (en) * 2021-12-09 2023-06-15 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease
JP2025504199A (ja) * 2022-02-07 2025-02-06 アルツェオン・インコーポレーテッド Ｃｏｖｉｄ－１９関連神経症状の治療に使用するためのａｌｚ－８０１

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600730A (zh) * 2006-10-12 2009-12-09 贝鲁斯健康(国际)有限公司 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0625212B1 (en) 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
KR20070120190A (ko) 2005-04-12 2007-12-21 뉴로켐 (인터내셔널) 리미티드 아밀로이드 억제 화합물의 제약 제제
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
PT2994160T (pt) 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
KR20240094017A (ko) * 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
PT3119911T (pt) 2014-03-21 2023-11-03 Alzheon Inc Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
HRP20230809T1 (hr) * 2015-09-10 2023-10-27 Alzheon, Inc. Liječenje alzheimerove bolesti u određenoj populaciji bolesnika

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600730A (zh) * 2006-10-12 2009-12-09 贝鲁斯健康(国际)有限公司 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions

Also Published As

Publication number Publication date
HK1257874A1 (en) 2019-11-01
CN116712423A (zh) 2023-09-08
US11191742B2 (en) 2021-12-07
EP3347002B1 (en) 2023-06-07
MD3347002T2 (ro) 2023-10-31
US20220096406A1 (en) 2022-03-31
CN108289870A (zh) 2018-07-17
KR102412997B1 (ko) 2022-06-23
RS64481B1 (sr) 2023-09-29
SMT202300250T1 (it) 2023-09-06
JP2020200352A (ja) 2020-12-17
HRP20230809T1 (hr) 2023-10-27
JP2022145949A (ja) 2022-10-04
US20230414541A1 (en) 2023-12-28
CA2997376C (en) 2024-05-14
AU2016319107A1 (en) 2018-03-22
JP6789579B2 (ja) 2020-11-25
PT3347002T (pt) 2023-07-27
JP2018526407A (ja) 2018-09-13
JP2025065545A (ja) 2025-04-17
KR20220042480A (ko) 2022-04-05
EP3347002A4 (en) 2019-04-24
PL3347002T3 (pl) 2023-11-13
CA2997376A1 (en) 2017-03-16
EP4275750A2 (en) 2023-11-15
WO2017044840A1 (en) 2017-03-16
HUE062511T2 (hu) 2023-11-28
KR102547164B1 (ko) 2023-06-22
EP3347002A1 (en) 2018-07-18
EP4275750A3 (en) 2024-01-17
AU2016319107B2 (en) 2021-02-25
DK3347002T3 (da) 2023-08-14
FI3347002T3 (fi) 2023-08-10
LT3347002T (lt) 2023-09-11
SI3347002T1 (sl) 2023-12-29
JP7128536B2 (ja) 2022-08-31
MX2022003128A (es) 2022-08-02
MX2018003023A (es) 2018-06-06
MX392677B (es) 2025-03-24
ES2952727T3 (es) 2023-11-03
KR20180051561A (ko) 2018-05-16

Similar Documents

Publication Publication Date Title
JP7128536B2 (ja) 特定の患者集団において神経変性障害を処置する方法
US11116773B2 (en) Method of treating dementia
US11690849B2 (en) Method of treating dementia
CN113939276A (zh) 用于治疗精神障碍、行为障碍、认知障碍的药物组合物和方法
CA3137393A1 (en) A method of treating mental, behavioral, cognitive disorders
US20100035927A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
HK40101454B (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: ALZHEON, Inc.

Address before: Massachusetts

Applicant before: ALZHEON, Inc.

CB02 Change of applicant information